Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial.
作者信息
Gragnano Felice, De Sio Vincenzo, Cesaro Arturo, Calabrò Paolo
机构信息
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta, 81100, Italy.
Division of Clinical Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, 81100, Italy.
出版信息
Future Cardiol. 2024;20(11-12):591-593. doi: 10.1080/14796678.2024.2388472. Epub 2024 Aug 12.
Abstract
摘要
相似文献
1
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial.急性冠状动脉综合征后替格瑞洛单药治疗：来自ULTIMATE-DAPT试验的经验教训。
Future Cardiol. 2024;20(11-12):591-593. doi: 10.1080/14796678.2024.2388472. Epub 2024 Aug 12.
2
De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical Trials.急性冠状动脉综合征中双联抗血小板治疗降级为替格瑞洛单药治疗：一项随机临床试验的系统评价和个体患者数据荟萃分析
Ann Intern Med. 2025 Apr;178(4):533-542. doi: 10.7326/ANNALS-24-03102. Epub 2025 Feb 18.
3
Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.支架置入后 1 个月内停用阿司匹林行替格瑞洛单药治疗急性冠状动脉综合征：T-PASS 随机非劣效性试验。
Circulation. 2024 Feb 20;149(8):562-573. doi: 10.1161/CIRCULATIONAHA.123.066943. Epub 2023 Oct 25.
4
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.比较血管内超声或血管造影指导下急性冠脉综合征患者药物洗脱支架植入术后 1 个月与 12 个月双联抗血小板治疗：前瞻性、多中心、随机、对照 IVUS-ACS 和 ULTIMATE-DAPT 试验的原理和设计。
Am Heart J. 2021 Jun;236:49-58. doi: 10.1016/j.ahj.2021.02.014. Epub 2021 Feb 20.
5
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.替格瑞洛单药治疗与替格瑞洛联合阿司匹林治疗对急性冠状动脉综合征患者主要出血和心血管事件的影响：TICO 随机临床试验。
JAMA. 2020 Jun 16;323(23):2407-2416. doi: 10.1001/jama.2020.7580.
6
Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial.替格瑞洛单药治疗与替格瑞洛联合阿司匹林治疗与年龄相关的主要出血和心血管事件的影响：TICO 随机试验的事后分析。
J Am Heart Assoc. 2021 Dec 21;10(24):e022700. doi: 10.1161/JAHA.121.022700. Epub 2021 Dec 7.
7
Insights on DAPT Abbreviation and De-escalation from ULTIMATE-DAPT and Related Trials: Are we Heading Toward an Aspirin-Free Strategy?来自ULTIMATE-DAPT及相关试验对双联抗血小板治疗（DAPT）缩写和降阶梯治疗的见解：我们正朝着无阿司匹林策略迈进吗？
Am J Cardiovasc Drugs. 2025 Mar 8. doi: 10.1007/s40256-025-00725-0.
8
9
Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol).比较替格瑞洛单药治疗与双重抗血小板治疗在经皮冠状动脉介入治疗后慢性冠状动脉综合征患者中的安全性和有效性的随机非劣效性临床试验的原理与设计（TICALONE-TAHA10方案）
PLoS One. 2025 Jul 16;20(7):e0325663. doi: 10.1371/journal.pone.0325663. eCollection 2025.
10
Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials.替格瑞洛单药治疗急性冠脉综合征：TICO 和 T-PASS 试验的个体患者数据分析荟萃分析。
Eur Heart J. 2024 Sep 1;45(33):3045-3056. doi: 10.1093/eurheartj/ehae249.
本文引用的文献
1
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis.急性冠状动脉综合征中短期 DAPT 后 P2Y12 抑制剂单药治疗：系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):588-598. doi: 10.1093/ehjcvp/pvae057.
2
Aspirin-Free Strategies After Complex PCI: Type of P2Y Inhibitor Matters.复杂经皮冠状动脉介入治疗后的无阿司匹林策略：P2Y 抑制剂类型很重要。
JACC Cardiovasc Interv. 2024 May 13;17(9):1131-1133. doi: 10.1016/j.jcin.2024.03.026.
3
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.血管内超声指导与血管造影指导的急性冠状动脉综合征经皮冠状动脉介入治疗（IVUS-ACS）：一项两阶段、多中心、随机试验。
Lancet. 2024 May 11;403(10439):1855-1865. doi: 10.1016/S0140-6736(24)00282-4. Epub 2024 Apr 8.
4
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.替格瑞洛单用或替格瑞洛加阿司匹林用于急性冠脉综合征患者经皮冠状动脉介入治疗后 1 至 12 个月（ULTIMATE-DAPT）：一项随机、安慰剂对照、双盲临床试验。
Lancet. 2024 May 11;403(10439):1866-1878. doi: 10.1016/S0140-6736(24)00473-2. Epub 2024 Apr 7.
5
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.替格瑞洛或氯吡格雷单药治疗与经皮冠状动脉介入治疗后双联抗血小板治疗：系统评价和患者水平荟萃分析。
JAMA Cardiol. 2024 May 1;9(5):437-448. doi: 10.1001/jamacardio.2024.0133.
6
Antiplatelet Therapy After PCI: The Art and Science of De-Escalation.PCI术后的抗血小板治疗：降阶梯治疗的艺术与科学
Circulation. 2024 Feb 20;149(8):601-604. doi: 10.1161/CIRCULATIONAHA.123.067767.
7
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
8
Balancing Benefits and Risks of Oral Antiplatelet Strategies in patients With Coronary Artery Diseases: An Evolving Issue.冠状动脉疾病患者口服抗血小板策略的获益与风险平衡：一个不断发展的问题。
Curr Probl Cardiol. 2023 Dec;48(12):102025. doi: 10.1016/j.cpcardiol.2023.102025. Epub 2023 Aug 6.
9
P2Y Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.P2Y 抑制剂或阿司匹林单药治疗用于冠心病事件的二级预防。
J Am Coll Cardiol. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051.
10
P2Y Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.复杂经皮冠状动脉介入治疗后 P2Y 抑制剂单药治疗或双联抗血小板治疗。
J Am Coll Cardiol. 2023 Feb 14;81(6):537-552. doi: 10.1016/j.jacc.2022.11.041.
Zotero 插件